CRISPR Therapeutics has been granted a patent for masked chimeric antigen receptor (CAR) constructs targeting tyrosine-protein kinase-like 7 (PTK7). The masked CAR includes an antigen binding domain and a mask peptide to prevent binding to PTK7. Genetically engineered T cells expressing this CAR have therapeutic potential. GlobalData’s report on CRISPR Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights CRISPR Therapeutics AG - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CRISPR Therapeutics, CRISPR genome editing was a key innovation area identified from patents. CRISPR Therapeutics's grant share as of February 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.

Masked car for ptk7 with therapeutic uses

Source: United States Patent and Trademark Office (USPTO). Credit: CRISPR Therapeutics AG

A recently granted patent (Publication Number: US11926676B2) discloses a masked chimeric antigen receptor (CAR) specific to tyrosine-protein kinase-like 7 (PTK7). The masked CAR includes an extracellular antigen binding domain with a single chain variable fragment (scFv) that binds PTK7, along with a mask peptide linked to the scFv via a protease cleavage site. The mask peptide, which can be 13-25 amino acids in length, is removable by protease cleavage at the site, with the protease cleavage site being a matrix metalloproteinase (MMP) cleavage site, specifically MMP14. Additionally, the masked CAR includes intracellular signaling domains, such as co-stimulatory domains like CD28 or 4-1BB, and a transmembrane domain like CD8.

Moreover, the patent covers genetically engineered T cells expressing the masked CAR, which can be created by delivering a nucleic acid encoding the masked CAR to T cells. These engineered T cells may have disrupted TRAC or B2M genes, with the nucleic acid encoding the masked CAR inserted at the site of the disruption. The patent also includes a method for producing these genetically engineered CAR-T cells, involving the delivery of the nucleic acid encoding the masked CAR to T cells to produce a population of genetically engineered T cells expressing the masked CAR. This innovation in CAR technology opens up possibilities for targeted therapy in conditions where PTK7 is implicated, with potential applications in cancer treatment and beyond.

To know more about GlobalData’s detailed insights on CRISPR Therapeutics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies